Puneet Souda

Kim attributed difference to tough comps (nearly 20% prior year) versus competitors comparing against negative numbers. Jim added that after backing out the one large OEM order, proteins and antibodies combined grew low single digits this quarter.

Jim affirmed mid-single-digit FY2027 target, noting that excluding 3 customer-specific items they would have been low single digit growth even in the current tough environment. Cited academic uptick in proteomic analysis and spatial as leading indicators.

Jim detailed underlying growth acceleration from 1% in Q1 to 3% in Q2 with slight step up in Q3, plus 3% comp tailwind in Q4. Kim cited accelerating core business, 30% ex-Fast Track cell therapy growth, and positive trends across growth verticals.

Kim cited China's fifteenth five-year plan prioritizing life sciences, exits from local biotech companies via M&A and licensing, and improving CDMO/CRO activity driving demand for reagents and proteomic tools.

Kim cited favorable grant mix aligned with Bio-Techne's research areas and bipartisan support for flat NIH budget. Jim provided detailed competitive positioning: core reagents flat but in line or taking share, ProteinSimple at mid-single-digit growth above market, spatial turning positive.

Kim confirmed clinical trial starts remain flat and steady with normal turnover. Noted market maturation with new programs better aligned to viable, scalable, affordable cell therapies versus the more speculative earlier cycle.

Jim clarified that low-single-digit guidance is conditional on uncertainty duration, not necessarily full-year FY2026. Declined to give segment-level guidance but indicated no big material change in either segment's growth rates.

Kim attributed instrument strength to QA/QC spec-ins at large pharma, the Leo high-throughput Simple Western launch, and biologics Maurice platform demand. Noted Lunaphore had three instrument placements delayed by Middle East political turbulence.

Kim deferred FY2026 guidance to the usual soft guide timing in three months. On China, noted tariffs are very negatable but acknowledged a step back to mid-single digits negative driven by tariffs and local economic weakness.

Jim explained Q4 step-down from non-repeating partner reagent orders, academic slowdown after February NIH announcements, and conservative pharma expectations given April 2 tariff escalation. Kim confirmed no Q3 pull-forward unlike Q2.

Kim explained GMP orders pulled from Q3 to Q2 at customers' request, adding several growth points. China stimulus seeing early traction with instrument sales. Jim noted broad-based pharma recovery beyond just cell therapy.

Kim outlined M&A focus on analytical platforms for novel biological insights and cell therapy workflow adjacencies, noting strong balance sheet and time before Wilson Wolf close in 2027.

Kim detailed sustainable momentum across ExoDx, Asuragen kits, and COMET spatial platform with strong R&D pipeline including ESR1 breast cancer test.

Kim confirmed 400 customers in funnel with 58 in clinical trial stages, growth from customer progression, increased order frequency from smaller accounts, and new customer additions.

Batra said GLP-1 testing grew over 40%, broad-based (Americas over 30%, Europe over 36%, India nearly doubling); Chaubal noted ~30bps of the 200bps idiosyncratic drivers.

Batra deferred detailed 2027 outlook but said BD exits 2026 north of 6% (from -10% a year ago); framed the 180-day commercial, pricing and China initiatives as systemic.

Amol quantified ~200bps price on legacy Waters (consistent with prior years) vs only 0.5% on BD (in line with BD historical). Sees meaningful opportunity to bring BD pricing to Waters levels. Pricing upside not in guide.

Amol noted CROs, Chinese generics, and biotechs still not replacing despite overaged fleets, giving runway into 2027. 2021-22 placements come up for replacement in 2029-30. Reshoring dynamic expected to bridge any 2028 air pocket.

Management clarified 2.5% BD growth guide does NOT include pricing improvements, deal desk benefits, or launch readiness gains. Only bakes in China DRG headwind and continued A&G softness.

CFO confirmed Q1 guide includes benefit from 4 extra working days which derisks the remainder of the year.

Management outlined 3-part Empower strategy: instrument compatibility, AI/ML features, and subscription transition with significant per-customer upside.

Management confirmed no pull-forward in Q3, with Q3-Q4 ramp of 16% prudently below the 18% last year and 22% historical average.

Management outlined instrument replacement, service attach and e-commerce as immediate day-one actions post-close.

A&G decline of -3% was better than expected; management maintained conservative high single-digit decline assumption for H2.

CFO broke down $45M gross tariff mitigation: $15M surcharges, $14M manufacturing actions, $6M discretionary spend cuts.

Management emphasized no slowdown in replacement discussions, with large pharma, generics and CDMOs all growing double digits.

CFO explained the wider range reflects working day impacts and macro uncertainty, with Q1 being the smallest quarter.

Management outlined the large patent cliff opportunity with semaglutide genericization expected in 2026.

Padraig cited an encouraging SMID biotech uptick as H1 biopharma financing doubled to $60B; Simon flagged mRNA oncology validation as future upside.

Management confirmed steady and increasing CAM momentum with technology-driven share gains in advanced materials at low double digit growth. Noted prudence in H2 outlook decelerating from high to mid single digits.

Management highlighted downstream QAQC and development positioning as sweet spot for reshoring and replacement cycle, with compounding Ignite benefits embedding structurally. Mid-sized biotech still challenged but deal activity improving.

Adam clarified small/mid biotech spending not yet inflecting, framed as upside scenario. Padraig added January biopharma financing at $11B (2-year high), patent cliff driving M&A, but lag between funding and spending. Relatively small Agilent exposure.

Adam confirmed CDMO business above corporate operating margin at steady state. Train C/D ramping through 2027 with negative margin impact offset by Ignite. Padraig added booked out for FY2026, now booking FY2027 with larger commercial batches.

Padraig broke down China: small molecule grew 6%, biopharma mid-single digits, CAM low teens on petrochemicals and semis. New innovation policy from central government. Mike Zhang added strong customer relationships and high win rates on stimulus. Comprehensive.

Padraig confirmed pickup in quoting and replacement activity July-August. Market share gains across all platforms and geographies. Momentum similar in pharma and CAM with replacement cycles at different stages. Direct.

Padraig clearly separated consumable pull-forward (tariff-driven), Lunar New Year (~2pp), and stimulus (mostly Q1). China stable above $300M. Comprehensive breakdown.

Padraig detailed 6-9 month funnel-to-close cycle, higher attach rates, gradual build across 1100/1260/1290 bases. Bob added small molecule QA/QC double-digit growth proof point.

Padraig reiterated win rate and pull-forward dynamics. Simon added multi-year stimulus context and increased confidence for H2. Made-in-China advantage highlighted.

Padraig cited 3-year Ignite framework. Bob confirmed on-track for 50-70bps this year despite FX headwinds, with pricing holding up.

Padraig confirmed minimal order pause from Infinity III launch, expressed strong satisfaction with order book. Direct and reassuring.

Padraig and Bob detailed manufacturing footprint: 60% US, small China-for-China exposure, manageable $4-5M quarterly tariff impact.

Management pointed to second-half software contract renewals and its LLM/Signals AI and Anthropic connector pipeline, but did not quantify the high-content backlog it was asked about.

Prahlad cited Gartner research paper highlighting RVTY's differentiated AI deployment. Benefits primarily in software development productivity. Rolling out multiple LLMs to entire global employee base at fraction of traditional cost.

Prahlad framed divestiture as completing portfolio transformation journey. China now 8-9% of revenue with ~7% in LS. Will continue both acquisitive strategy and aggressive buybacks.

Max confirmed 2-3% organic outlook assumes similar environment, not a huge ramp in market activity. Prahlad added all repro health and NBS manufacturing is local in China, and over half of IDx now local.

Prahlad confirmed improvement is genuine broader pharma/biotech activity, not China tariff-related normalization.

Prahlad detailed strong metrics: 21% ARR uplift, 115% net retention, 13% APV growth, over one-third now SaaS.

Prahlad defended portfolio citing LS reagents 5 consecutive quarters of growth, software 30%+, repro health strong, IDx ex-China very strong.

Prahlad minimized NIH concern: 1% direct, under 5% indirect, mostly reagents/small ticket items that still flow regardless.

Max confirmed low-double-digit software growth expected for full year and Q1. No one-timers flagged; predictable renewal pattern.

Jacob agreed clinical is a wave not a cliff and cited elevated placements, but stayed committed to high single-digit 2027 growth for now.

Jacob said clinical placements are largely incremental (not conversions), driving immediate top-line growth; Ankur confirmed pricing transition assumptions are unchanged.

Jacob said clinical drove over 60% of the 100+ placements; mid-throughput remains macro-challenged, and Ankur saw little competitive impact in Q4.

Jacob cited the OEM local-manufacturing approval as progress but declined a 2026 China view, taking it quarter by quarter.

Jacob reported no pull-forward and rising backlog as customers plan X in production mode; no cliff expected in the clinical transition.

Jacob declined to comment on timelines or reversal, citing early-stage dialogue.

Book-to-bill around 1, consistent with the year. mAb growth remains the core driver at 75% of business, commercial volumes growing, new indications, biosimilars approaching launch. AAV is small and lapping.

Rainer noted the 20% local manufacturing preference has been informally in place. By year-end, much of diagnostic equipment and reagents will be localized. Views this as an advantage, not a headwind.

Rainer framed Danaher as a protein-focused house (85% of business). Aldevron-Sarepta revenue expected at $30M for full year with minimal H2 contribution. AAV gene therapy in early innings.

Tariff exposure down to approximately $200M from $350M initial estimate. Company absorbed China tariff costs without passing to customers, making it a net neutral event.